Hanmi's IMD AmosartanQ will be launched in the Russian market through Sanofi.

Hanmi announced on the 20th that Sanofi has obtained marketing approval from the MOH for AmosartanQ under the product name Tristanium.

AmosartanQ is a combination drug that combines Amlodipine Camsylate, a component for treating hypertension of CCB, and Losartan potassium, a component for treating hypertension of ARB, and Rosuvastatin Calcium, a component for treating hyperlipidemia.

Sanofi is in charge of local licensing, sales marketing, and sales in Russia by receiving the right to use exclusive Russian license materials for AmosartanQ from Hanmi. This time, with the marketing approval, it is p